Emcure Pharmaceuticals has announced the nationwide commercial rollout of Poviztra, a semaglutide-based injection indicated for weight management. With this launch, Emcure becomes the first Indian company to exclusively distribute and market Poviztra in the country. The drug is Novo Nordisk’s second branded formulation of semaglutide for weight loss, according to a company statement.
Poviztra will be offered as a once-weekly injectable pen in five dosage strengths 0.25 mg, 0.5 mg, 1.0 mg, 1.7 mg and a 2.4 mg maintenance dose. The treatment will be priced from Rs 8,790 per month for a pack of four weekly injections.
The pen device has been developed to ensure ease of use and accurate dosing.
The drug is prescribed alongside a calorie-restricted diet and increased physical activity for long-term weight management in adults with a body mass index (BMI) of 30 kg/m² or above, especially those with associated conditions such as hypertension, type 2 diabetes or dyslipidaemia. It is also approved to help lower the risk of major adverse cardiovascular events in adults.
Commenting on the launch, Emcure Pharmaceuticals CEO and Managing Director Satish Mehta said India is witnessing a growing obesity burden, with around 254 million people affected by general obesity and a further 351 million by abdominal obesity. He added that the launch of Poviztra represents a step towards improving access to evidence-based weight-management therapies.
